LEE011 strategy

Novartis (NVS) has been striving to differentiate its investigational oncology drug, LEE011, from other breast cancer drugs in three areas. The company aims to strengthen the position of LEE011 by building maximum data to support the drug for first-line metastatic breast cancer treatment. Novartis also plans to test the potential of the drug in pre-specified patient subpopulations. Finally, the company is also working on other investigational programs involving selective estrogen receptor degraders and other novel agents that can support the LEE011 label expansion in future years.

If Novartis manages to successfully implement this differentiation strategy for LEE011, it could have a positive impact on the company’s stock as well as the Vanguard FTSE All-World ex-US ETF (VEU). Novartis makes up about 0.74% of VEU’s total portfolio holdings.

Investigational Breast Cancer Drug Could Boost Novartis’s Position


On May 18, 2016, Novartis announced that the independent data monitoring committee had recommended the company stop its mammary oncology assessment of LEE011’s efficacy and safety-2 (or MONALEESA-2) phase three trial after the pre-planned interim analysis. The trial was stopped earlier than scheduled, as the investigational combination therapy managed to meet its primary endpoint and demonstrated statistically significant improvement in progression-free survival as compared to letrozole monotherapy.

Based on these results, Novartis has filed an application with the FDA seeking approval for combination therapy LEE011 and letrozole as first-line breast cancer therapy. The FDA has granted priority review status to this new drug application (or NDA). Novartis expects to receive approval for this regimen in 2Q17. The company also anticipates regulatory approval from the European Medicines Agency (or EMA) in 2H17.

LEE011 is thus expected to enable Novartis to pose tough competition to other oncology players such as Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb (BMY).

In the next article, we’ll explore Novartis’s efforts to expand LEE011’s label across multiple patient subpopulations in greater detail.

Latest articles

This morning before the market opened, Tesla (TSLA) was trading on a negative note despite a sharp rise in index futures. As of 9:10 AM ET, Tesla stock had fallen 1.2% in the pre-market session to $234.74 after Goldman Sachs cut the target price on the company by about 21%.

The US-China trade war has already given a scare to Apple’s (AAPL) investors vis-à-vis the possibility of a 25% tariff on Apple goods being imported from its Chinese facilities. As a result, Apple might be considering shifting its plants out of China.

Yesterday, Greenlane Holdings (GNLN) fell a whopping 17.1%. The stock has now fallen 28% this month, and it hit its all-time low yesterday. Greenlane Holdings listed in April and priced its IPO at $17 per share. However, since the stock surged more than 25% after its listing, it has been a sorry story for Greenlane Holdings investors.

Yesterday, Mexico ratified the USMCA. The agreement was negotiated last year and would replace the 25-year-old NAFTA. The United States and Canada are yet to ratify the agreement. Renegotiating NAFTA was among Trump’s prominent campaign promises.

On June 20, Darden Restaurants (DRI) reported its fourth-quarter results. For the quarter ending May 26, the company posted an adjusted EPS of $1.76, which beat analysts’ expectation of $1.73.

20 Jun

GE Aviation Bags $55 Billion in Orders at the Paris Air Show

WRITTEN BY Mayur Sontakke, CFA, FRM

On June 20, GE Aviation published a press release stating that the company and CFM International had bagged $55 billion worth of new orders at the Paris Air Show—and with three more days to go before the closure of the show, there could be further additions to its orderbook.